Your browser is no longer supported. Please, upgrade your browser.
Settings
VRDN [NASD]
Viridian Therapeutics, Inc.
Index- P/E- EPS (ttm)-29.00 Insider Own6.10% Shs Outstand3.94M Perf Week-7.13%
Market Cap118.50M Forward P/E- EPS next Y-1.60 Insider Trans0.00% Shs Float3.58M Perf Month-14.61%
Income-110.70M PEG- EPS next Q-0.76 Inst Own37.40% Short Float2.63% Perf Quarter-29.91%
Sales1.10M P/S107.73 EPS this Y-55.30% Inst Trans219.49% Short Ratio2.23 Perf Half Y70.81%
Book/sh-15.44 P/B- EPS next Y41.00% ROA-187.20% Target Price- Perf Year107.00%
Cash/sh16.55 P/C0.93 EPS next 5Y- ROE- 52W Range6.75 - 25.67 Perf YTD-6.57%
Dividend- P/FCF- EPS past 5Y37.10% ROI181.50% 52W High-40.12% Beta1.64
Dividend %- Quick Ratio12.10 Sales past 5Y-16.20% Gross Margin- 52W Low127.70% ATR1.04
Employees26 Current Ratio12.10 Sales Q/Q-88.90% Oper. Margin- RSI (14)38.45 Volatility4.91% 6.07%
OptionableNo Debt/Eq- EPS Q/Q-392.10% Profit Margin- Rel Volume0.32 Prev Close15.73
ShortableYes LT Debt/Eq- EarningsMar 25 AMC Payout- Avg Volume42.29K Price15.37
Recom1.50 SMA20-10.56% SMA50-13.44% SMA200-5.08% Volume13,697 Change-2.29%
Jan-25-21Initiated Ladenburg Thalmann Buy $40
Mar-25-21 04:05PM  
02:30PM  
Mar-23-21 04:00AM  
Mar-09-21 04:30PM  
Feb-22-21 08:00AM  
07:45AM  
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.